v3.26.1
General (Details)
$ / shares in Units, € in Thousands
6 Months Ended 12 Months Ended
Aug. 19, 2026
shares
Mar. 03, 2026
USD ($)
shares
Mar. 02, 2026
USD ($)
shares
Feb. 27, 2026
EUR (€)
Feb. 16, 2026
$ / shares
Mar. 24, 2025
USD ($)
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2026
EUR (€)
shares
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
shares
Jun. 30, 2026
EUR (€)
Feb. 16, 2026
EUR (€)
Sep. 30, 2025
USD ($)
Sep. 10, 2025
USD ($)
Mar. 27, 2025
General [Line Items]                              
Incorporated date             Jul. 21, 2003 Jul. 21, 2003              
Total consideration           $ 1,000 $ 200,000                
Diluted share capital             100.00%       100.00%        
Percentage of share capital and voting rights                             100.00%
Total research and development expenses             $ 839,000   $ 1,237,000            
Aggregate purchase price per share | $ / shares         $ 1                    
Nominal consideration value | €                     € 1        
Gain from bargain purchase             6,401,000              
Acquired business contributed net loss             $ 2,058,000                
Non-dilutive grant fund amount                 $ 12,000,000            
Percentage of the lowest daily volume weighted average price             97.00% 97.00%              
Commitment fee                           $ 108,000  
ADSs [Member]                              
General [Line Items]                              
Conditions of the agreement   $ 10,000,000                          
Shares issued | shares 1 2,878               220,000,000          
Issuance related costs   $ 150,000                          
Aggregate gross proceeds             $ 15,000,000     $ 5,800,000          
Business Combination [Member]                              
General [Line Items]                              
Acquired business contributed revenues             654,000                
Recipharm Israel Ltd. [Member]                              
General [Line Items]                              
Percentage of remaining payable in cash             $ 0.50                
YA [Member]                              
General [Line Items]                              
Cash     $ 5,000                        
Percentage was satisfied upon execution             50.00% 50.00%              
Commitment fee     $ 11,000       $ 108,000           $ 5,000    
YA [Member] | ADSs [Member]                              
General [Line Items]                              
Shares issued | shares     1,248       3,546 3,546              
Option Agreement [Member]                              
General [Line Items]                              
Other payables                   50,000          
Liability                   50,000          
Remaining paid amount                   150,000          
Development funding amount             $ 3,000,000                
Total research and development expenses                   $ 250,000          
Monthly payments on options | €       € 13                      
Non-dilutive grant fund amount | €               € 11,000              
Additional cancellation fee payable             $ 50,000                
Option Agreement [Member] | PinCell’s [Member]                              
General [Line Items]                              
Operating activities | €       € 80                      
Share Purchase Agreement [Member]                              
General [Line Items]                              
Nominal consideration value | €                       € 1      
Share Purchase Agreement [Member] | Recipharm Israel Ltd. [Member]                              
General [Line Items]                              
Percentage of issued and outstanding share capital         100.00%                    
Cash | €                       € 2,000